NCT04837196 2025-08-08Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 AntigenAstellas Pharma IncPhase 1/2 Completed24 enrolled 47 charts
NCT04949191 2024-09-19The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.Incyte CorporationPhase 2 Terminated10 enrolled 9 charts